English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The NAGOYA HEART Study1 compared the efficacies of an angiotensin II type 1 receptor blocker (ARB) valsartan and a calcium channel blocker amlodipine on cardiovascular morbidity and mortality as a primary outcome in Japanese hypertensive patients with glucose intolerance. Time-to-event curves for primary outcomes did not significantly differ between the 2 groups (hazard ratio, 0.97; 95% confidence interval [CI], 0.66–1.40; P =0.85). Despite no significant differences in the risk of myocardial infarction, stroke, coronary revascularization, or sudden cardiac death between the 2 groups, the incidence of admission because of heart failure was significantly less in the valsartan group than that in the amlodipine group (hazard ratio, 0.20; 95% CI, 0.06–0.69; P =0.012). It seems strange, however, that the achieved blood pressure (BP) between the 2 groups is almost the same (131/73 mm Hg in the valsartan group and 132/74 mm Hg in the amlodipine group at 54 months). Herein, we would like to assess the specificity of the significant relative risk reduction for heart failure with …

Concerns for the Heart Failure Reduction in the NAGOYA HEART Study Based on Meta-Regression From the Evidence